BWS Financial Downgrades Insulet (PODD) to Hold
More News related to PODD
- Insulet Corporation to Present at the Piper Jaffray Health Care Conference
- Insulet (PODD) Announces Pricing of 6M Common Share Offering at $10.25/Share
- Insulet Corporation Announces Pricing of Public Offering
- Morning Movers 10/29: ROIAK, GIGA, HS, TBL, KDN, CATM Higher; TSPT, CPF, CYTK, KSP, FSLR, CLUB, PODD Lower
- Insulet (PODD) to Offer 5.5M Common Shares
More News related to Downgrades
- Shields & Co. Downgrades ALLETE, Inc. (ALE) to Hold
- Scotia Capital Downgrades Grupo Aeroportuario del Centro (OMAB) to Sector Perform
- Goldman Sachs Upgrades Bradesco and Banco do Brasil; Downgrades Bancolombia
- Wedbush Downgrades Burger King (BKC) to Underperform
- Morgan Stanley Upgrades Safeway (SWY), Downgrades SUPERVALU (SVU)
BWS Financial downgrades Insulet (Nasdaq: PODD) from Buy to Hold. Price target lowered to $6.
Insulet Corporation is a medical device company engaged in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes.
Related Categories
DowngradesStocks Mentioned
-0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
